"Despite the rallies losing fizz, downside momentum did not dominate suggesting that the 9500-9550 objective is still in play, atleast as long as Nifty stays above 9,430. A direct fall below 9,386 could dilute the bullish bias, but a collapse is ruled out, atleast until VIX or other indicators signal," said Geojit Financial Services in a technical note.
Buzzing stocks
Dr Reddy’s Laboratories hit 52-week low of Rs 2,554 in intra-day trade ahead of its January-March quarter (Q4FY17) results today. Since February 3, post October-December (Q3FY17) results, the stock of drug Company has underperformed the market by falling 19% as compared to 7% rise in the S&P BSE Sensex.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)